Insulin is the mainstay of current treatment for patients with type 1 diabetes mellitus (T1DM). Due to increasing insulin resistance, insulin doses are often continually increased, which may result in weight gain for patients. Medications currently approved for the treatment of type 2 diabetes offer varying mechanisms of action that can help to reduce insulin resistance and prevent or deter weight gain. A MEDLINE search was conducted to review literature evaluating the use of metformin, alpha-glucosidase inhibitors, pioglitazone, glucagon-like peptide 1 agonists, dipeptidyl peptidase, and sodium-dependent glucose transporter 2 inhibitors, in patients with T1DM. Varying results were found with some benefits including reductions in hemoglobin A1c, decreased insulin doses, and favorable effects on weight. Of significance, a common fear of utilizing multiple therapies for diabetes treatment is the risk of hypoglycemia, and this review displayed limited evidence of hypoglycemia with multiple agents.
Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
2.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):s81–s90.
3.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
4.
GargV. Noninsulin pharmacological management of type 1 diabetes mellitus. Indian J Endocrinol Metabol. 2011;15(suppl 1):s5–s11.
5.
PangTTNarendranP. Addressing insulin resistance in type 1 diabetes. Diabet Med. 2008;25(9):1015–1024.
6.
HamiltonJCummingsEZdravkovicV. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance. Diabetes Care. 2003;26(1):138–143.
7.
SarnbladSKroonMAmanJ. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323–329.
8.
KhanASMcLoughneyCRAhmedAB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med. 2006;23(10):1079–1084.
9.
JacobsenIHenriksenJBeck-NielsenH. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol. 2009;105(3):145–149.
10.
MeyerLBohmePDelbachianI. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care. 2002;25(12):2153–2158.
11.
LundSTarnowLAstrupA. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One. 2008;3(10):e3363.
12.
MoonRJBascombeLAHoltRI. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well being. Diabetes Obes Metabol. 2007;9(1):143–145.
13.
PaganoGTagliaferroVCartaQ. Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia. 1983;24(5):351–354.
14.
PitoccoDZaccardiFTarziaP. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obes Metabol. 2013;15(5):427–431.
15.
NagaiEKatsunoTMiyagawaJ. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J. 2011;58(10):869–877.
16.
HollanderPPi-SunyerXConiffR. Acarbose in the treatment of type 1 diabetes. Diabetes Care. 1997;20(3):248–253.
17.
SelsJPVerdonkHEWolffenbuttelBH. Effects of acarbose (GLucobay®) in persons with type 1 diabetes: a multicentre study. Diabetes, Res Clin Pract. 1998;41(2):139–145.
18.
SharifiFGhazi SaidiMMousavi NasabN. Effects of acarbose in metabolic control of patients with type 1 diabetes mellitus. Int J Endocrinol Metab. 2008;1:13–19.
19.
DashSCrispSHartnellS. Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 2012;95(3):e49–e51.
20.
RiccardiGGiaccoRParilloM. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicenter study. Diabet Med. 1999;16(3):228–232.
21.
Juntti-BerggrenLPigonJHellstromP. Influence of acarbose on post-prandial insulin requirements in patients with type 1 diabetes. Diab Nutr Metab. 2000;13(1):7–12.
22.
BhatRBhansaliABhadadaS. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract. 2007;78(3):349–354.
23.
ZdravkovicVHamiltonJKDanemanD. Pioglitazone as adjuctive therapy in adolescents with type 1 diabetes. J Pediatr. 2006;149(6):845–849.
24.
KawanoYIrieJNakataniH. Pioglitazone might prevent the progression of slowly progressive type 1 diabetes. Intern Med. 2009;48(12):1037–1039.
25.
KielgastUHolstJMadsbadS. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes. 2011;60(5):1599–1607.
26.
BosiE. Time for testing incretin therapies in early type 1 diabetes?J Clin Endocrinol Metab. 2010;95(6):2607–2609.
27.
KielgastUAsmarMMadsbadS. Effect of glucagon-like peptide-1 on α- and β-cell function in c-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab. 2010;95(5):2492–2496.
28.
RotherKISpainLMWesleyRA. Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32(12):2251–2257.
29.
RamanVSMasonKJRodriguezLM. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33(6):1294–1296.
30.
Hari KumarKVSShaikhAPrustyP. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract. 2013;100(2):e55–e58.
31.
KielgastUKrarupTHolstJJ. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function. Diabetes Care. 2011;34(7):1463–1468.
32.
GargSKMoserEGBodeBW. Effect of sitagliptin on postprandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocrine Pract. 2013;19(1):19–28.
33.
KutohE. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. J Med Case Rep. 2011;5:117.
34.
EllisSLMoserEGSnell-BergeonJK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28(10):1176–1181.
35.
GiampietroOGiampietroCBartolaLD. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy and respond differently in type 1 and type 2 diabetes. Drug Des Devel Ther. 2013;7:99–104.
36.
FarngrenJPerssonMSchwizerA. Vidagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10)3799–3806.
37.
MudallarSArmstrongDMavianA. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35(11):2198–2200.
38.
ChenLHLeungPS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(5):392–402.
39.
LundSSTarnowLAstrupAS. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11(10):966–977.
40.
Precose®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
41.
Glyset®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
42.
Glucophage®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
43.
Glucophage ER®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
44.
Actos®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
45.
Byetta®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
46.
Bydureon®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
47.
Victoza®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
48.
Januvia®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
49.
Onglyza®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
50.
Tradjenta®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
51.
Invokana®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
52.
Lantus®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
53.
Levemir®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
54.
Novolog®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
55.
Humalog®. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
56.
Nesina. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
57.
Insulin standard NPH. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
58.
NovolinR. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
59.
Apidra. RED BOOK Online® [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc; 2013.
